Sign up
NVO

Novo Nordisk A/S (NYSE: NVO)

Healthcare · Drug Manufacturers - General

——

Quote unavailable · Price data is temporarily unavailable.

Set alert

The Quantellect read. Short interest is 1.21% of float with a 0.28% borrow fee. Descriptive summary of the data on this page, not a recommendation.

Relative valuation—

—

MomentumNeutral

RSI (14) 55.9 (overbought above 70, oversold below 30)

Trend—

—

Short interest1.2% of float

FINRA settlement Oct 30, 2026

NVO price chart

Price — · As of —

Open full chart →
Price details unavailable for this range.

Chart loads when this section enters view.

Text price and event history
6M plotted price range (ET)
Range6M
First date—
Last date—
Open—
High—
Low—
Close—
Volume—
Plotted bars0

Plotted OHLCV bars

No price bars are available for this range.

Event records

Event records load after the price chart.

Split-adjusted daily prices · Price as of —

Initial 6M price range summary
Range6M
First close—
Last close—
High—
Low—
Volume—
Open—
Previous close—
Day range—
52-week range
$34.77 – $61.72Through Nov 18, 2026
Volume—
Average volume (30 calendar days, 0 sessions)
—Through Nov 18, 2026
Market cap$176.43B
P/E (TTM)10.3
Forward P/E12.1
EPS (TTM)stale vendor snapshot —
Dividend yielddata unavailable —
Beta (5-year monthly vs SPY)—

Price history

NVO · NYSE · USD

Split-adjusted · volume in shares

Price history unavailable

Notable price movement

— · Notable price movement not available

Options flow

— · Options flow not available

Q Score

— · Q Score not available

Quantellect signals

Change since Nov 18

Insufficient data · Observed Nov 13, 2026, 6:33 PM ET

Squeeze21Idle—
Social Pulse

30 mentions in 24h

How the scores work →

Industry comparison

— · Industry comparison not available

Upcoming events

— · Upcoming events not available

Analyst consensus

— · Analyst consensus not available

Earnings history

— · Earnings history not available

Smart-money activity

— · Smart-money activity not available

All smart-money activity →

News and press releases

All NVO news →

Company profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The

CEO
—
Headquarters
Bagsvaerd, Denmark
Employees
66,700
IPO date
Jan 4, 1982
Sector
Healthcare
Industry
Drug Manufacturers - General

Data sources: exchange quotes delayed 15 minutes, FINRA short interest, SEC filings, OPRA options data and third-party analyst data. Education only. Nothing on this page is a recommendation to buy or sell a security.